The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ...

Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.

By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...

US FDA reviews a petition to revoke approval of Roche’s top-selling drug ocrelizumab to treat primary progressive multiple sclerosis: Bristol, UK Thursday, April 16, 2026, 15:00 ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the ...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...

The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of ...